# OnCo record fortitude-101 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/fortitude-101/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "fortitude-101", "NCT05052801" ;
  schema:name "FORTITUDE-101"@en ;
  schema:description "A new target, FGFR2b, showed a survival gain at first look that shrank with longer follow-up, and the trial did not include the immunotherapy patients now routinely get."@en ;
  schema:url <https://onco.cc/trials/fortitude-101/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05052801>, <https://www.annalsofoncology.org/article/S0923-7534(25)04862-8/fulltext> ;
  onco:status "mixed" ;
  onco:phase "3" ;
  schema:startDate "2022-03-07" ;
  onco:cancers <https://onco.cc/cancers/gastric/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/fgfr2/> ;
  onco:drugs <https://onco.cc/drugs/bemarituzumab/>, <https://onco.cc/drugs/folfox/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:people <https://onco.cc/people/zev-wainberg/> .